Targeting the apoptotic pathway with BCL-2 inhibitors sensitizes primary chronic lymphocytic leukemia to VSV-induced oncolysis

被引：0
|
作者：
Tumilasci, Vanessa F. [1 ,3 ]
Oliere, Stephanie [1 ,3 ]
Bell, John [2 ]
Hiscott, John [1 ,3 ]
机构：
[1] McGill Univ, Mol Oncol Grp, Lady Davis Inst, Jewish Gen Hosp, Montreal, PQ H3T 1E2, Canada
[2] Univ Ottawa, Ottawa Hlth Res Inst, Ottawa, ON, Canada
[3] McGill Univ, Dept Microbiol & Immunol, Ottawa, ON, Canada
来源：
CYTOKINE | 2008年 / 43卷 / 03期
关键词：
D O I：
10.1016/j.cyto.2008.07.262
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：287 / 287
页数：1
相关论文
共 50 条
  • [21] Targeting the apoptotic and autophagic pathway to augment oncolytic virotherapy of chronic lymphocytic leukemia
    Samuel, Sara
    Richards, Stephanie
    VanGrevenynghe, Julien
    Luco, Stephanie
    Shamy, April
    Abesada, Guillermo
    Hiscott, John
    CYTOKINE, 2011, 56 (01) : 87 - 87
  • [22] Bcl-2 family gene expression and Bcl-2 phopshorylation status in chronic lymphocytic leukemia.
    Viswanathan, S
    Saxena, A
    FASEB JOURNAL, 1998, 12 (05): : A810 - A810
  • [23] Development of a flow cytometric method for quantification of BCL-2 family members in chronic lymphocytic leukemia and correlation with sensitivity to BCL-2 family inhibitors
    Smith, Morey L.
    Chyla, Brenda
    McKeegan, Evelyn
    Tahir, Stephen K.
    CYTOMETRY PART B-CLINICAL CYTOMETRY, 2017, 92 (05) : 331 - 339
  • [24] The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells
    Kabore, Albert F.
    Sun, Jimnie
    Hu, Xiaojie
    McCrea, Kristin
    Johnston, James B.
    Gibson, Spencer B.
    APOPTOSIS, 2006, 11 (07) : 1175 - 1193
  • [25] The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells
    Albert F. Kabore
    Jinmie Sun
    Xiaojie Hu
    Kristin McCrea
    James B. Johnston
    Spencer B. Gibson
    Apoptosis, 2006, 11 : 1175 - 1193
  • [26] Prognostic significance of bcl-2 expression in chronic lymphocytic leukemia.
    Mapara, MY
    Bommert, K
    Bargou, R
    Daniel, PT
    Stilgenbauer, S
    Benner, A
    Lichter, P
    Dorken, B
    Dohner, H
    BLOOD, 1997, 90 (10) : 398 - 398
  • [27] Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia
    Del Principe, Maria Ilaria
    Dal Bo, Michele
    Bittolo, Tamara
    Buccisano, Francesco
    Rossi, Francesca Maria
    Zucchetto, Antonella
    Rossi, Davide
    Bomben, Riccardo
    Maurillo, Luca
    Cefalo, Mariagiovanna
    De Santis, Giovanna
    Venditti, Adriano
    Gaidano, Gianluca
    Amadori, Sergio
    de Fabritiis, Paolo
    Gattei, Valter
    Del Poeta, Giovanni
    HAEMATOLOGICA, 2016, 101 (01) : 77 - 85
  • [28] Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
    Roberts, Andrew W.
    Davids, Matthew S.
    Pagel, John M.
    Kahl, Brad S.
    Puvvada, Soham D.
    Gerecitano, John F.
    Kipps, Thomas J.
    Anderson, Mary Ann
    Brown, Jennifer R.
    Gressick, Lori
    Wong, Shekman
    Dunbar, Martin
    Zhu, Ming
    Desai, Monali B.
    Cerri, Elisa
    Enschede, Sari Heitner
    Humerickhouse, Rod A.
    Wierda, William G.
    Seymour, John F.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (04): : 311 - 322
  • [29] The role of proteasome inhibitors and the trail apoptotic pathway in the treatment of chronic lymphocytic leukemia.
    McCrea, KE
    Kabore, A
    Johnston, JB
    Gibson, SB
    BLOOD, 2005, 106 (11) : 334B - 334B
  • [30] Mitochondrial Apoptotic Priming Is Associated with Clinical Response to the Bcl-2 Antagonist ABT-199 in Chronic Lymphocytic Leukemia
    Davids, Matthew S.
    Deng, Jing
    Ryan, Jeremy
    Fernandes, Stacey M.
    Brown, Jennifer R.
    Letai, Anthony G.
    BLOOD, 2014, 124 (21)
12345